No effect of menstrual cycle on LDL oxidizability and particle size

Maturitas

Volumn 57, Issue 3, 2007, Pages 253-260

  Ruiz Sanz, José Ignacio ^a   Navarro, Rosaura ^a   Martínez, Rosa ^a   Hernández, M Luisa ^a   Matorras, Roberto ^b   Ruiz Larrea, M Begoña ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b HOSPITAL DE CRUCES   (Spain)

Author keywords

Tocopherol; 17 Estradiol; Female sex hormone; Free radical; Low density lipoprotein

Indexed keywords

2,2' AZOBIS(2 AMIDINOPROPANE); ALPHA TOCOPHEROL; COPPER ION; ESTRADIOL; FATTY ACID; FOLLITROPIN; LOW DENSITY LIPOPROTEIN; LUTEINIZING HORMONE; PROGESTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLICULAR PHASE; FOLLITROPIN BLOOD LEVEL; GAS CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IMMUNOASSAY; LIGHT SCATTERING; LIPID OXIDATION; LIPOPROTEIN BLOOD LEVEL; LUTEAL PHASE; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; NORMAL HUMAN; PARTICLE SIZE; PREMENOPAUSE; PROGESTERONE BLOOD LEVEL; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

ADULT; ALPHA-TOCOPHEROL; AMIDINES; CHOLESTEROL, LDL; COPPER; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MENSTRUAL CYCLE; OXIDATION-REDUCTION; PARTICLE SIZE; PREMENOPAUSE; PROGESTERONE;

EID: 34249993138     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2007.01.008     Document Type: Article

References (38)

1. Lerner D.J., and Kannel W.B. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 111 (1986) 383-390
2. Rossouw J.E. Hormones, genetic factors, and gender differences in cardiovascular disease. Cardiovasc Res 53 (2002) 550-557
3. Hamelin B.A., Methot J., Arsenault M., et al. Influence of the menstrual cycle on the timing of acute coronary events in premenopausal women. Am J Med 114 (2003) 599-602
4. Witteman J.C., Grobbee D.E., Kok F.J., Hofman A., and Valkenburg H.A. Increased risk of atherosclerosis in women after the menopause. BMJ 298 (1989) 642-644
5. Subbiah M.T. Mechanisms of cardioprotection by estrogens. Proc Soc Exp Biol Med 217 (1998) 23-29
6. Paganini-Hill A., Dworsky R., and Krauss R.M. Hormone replacement therapy, hormone levels, and lipoprotein cholesterol concentrations in elderly women. Am J Obstet Gynecol 174 (1996) 897-902
7. Soma M.R., Osnago-Gadda I., Paoletti R., et al. The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Int Med 153 (1993) 1462-1468
8. Collins P., Shay J., Jiang C., and Moss J. Nitric oxide accounts for dose-dependent estrogen-mediated coronary relaxation after acute estrogen withdrawal. Circulation 90 (1994) 1964-1968
9. Alvarez A., Hermenegildo C., Issekutz A.C., Esplugues J.V., and Sanz M.J. Estrogens inhibit angiotensin II-induced leukocyte-endothelial cell interactions in vivo via rapid endothelial nitric oxide synthase and cyclooxygenase activation. Circ Res 91 (2002) 1142-1150
10. Hwang J., Rouhanizadeh M., Hamilton R.T., et al. 17beta-Estradiol reverses shear-stress-mediated low density lipoprotein modifications. Free Radic Biol Med 41 (2006) 568-578
11. Koh K.K., Mincemoyer R., Bui M.N., et al. Effects of hormone-replacement therapy on fibrinolysis in postmenopausal women. N Engl J Med 336 (1997) 683-690
12. Salomaa V., Rasi V., Pekkanen J., et al. Association of hormone replacement therapy with hemostatic and other cardiovascular risk factors. The FINRISK Hemostasis Study. Arterioscler Thromb Vasc Biol 15 (1995) 1549-1555
13. Chiantera V., Sarti C.D., Fornaro F., et al. Long-term effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 10 (2003) 286-291
14. Christodoulakos G., Lambrinoudaki I., Panoulis C., Rizos D., Coutoukos J., and Creatsas G. Effect of raloxifene, estrogen, and hormone replacement therapy on serum homocysteine levels in postmenopausal women. Fertil Steril 79 (2003) 455-456
15. Hwang J., Peterson H., Hodis H.N., Choi B., and Sevanian A. Ascorbic acid enhances 17 beta-estradiol-mediated inhibition of oxidized low density lipoprotein formation. Atherosclerosis 150 (2000) 275-284
16. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
17. Maziere C., Auclair M., and Maziere J.C. Lipophilic beta-blockers inhibit monocyte and endothelial cell-mediated modification of low density lipoproteins. Biochim Biophys Acta 1126 (1992) 314-318
18. Rifici V.A., and Khachadurian A.K. The inhibition of low-density lipoprotein oxidation by 17-beta estradiol. Metabolism 41 (1992) 1110-1114
19. Shwaery G.T., Vita J.A., and Keaney Jr. J.F. Antioxidant protection of LDL by physiologic concentrations of estrogens is specific for 17-beta-estradiol. Atherosclerosis 138 (1998) 255-262
20. Arteaga E., Rojas A., Villaseca P., Bianchi M., Arteaga A., and Duran D. In vitro effect of estradiol, progesterone, testosterone, and of combined estradiol/progestins on low density lipoprotein (LDL) oxidation in postmenopausal women. Menopause 5 (1998) 16-23
21. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
22. Herrington D.M., Vittinghoff E., Lin F., et al. Statin therapy, cardiovascular events, and total mortality in the Heart and Estrogen/Progestin Replacement Study (HERS). Circulation 105 (2002) 2962-2967
23. Sherman A.M., Shumaker S.A., Kancler C., et al. Baseline health-related quality of life in postmenopausal women with coronary heart disease: the Estrogen Replacement and Atherosclerosis (ERA) trial. J Womens Health (Larchmt) 12 (2003) 351-362
24. Austin M.A., Breslow J.L., Hennekens C.H., Buring J.E., Willett W.C., and Krauss R.M. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260 (1988) 1917-1921
25. Tribble D.L., Holl L.G., Wood P.D., and Krauss R.M. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 93 (1992) 189-199
26. Wakatsuki A., Okatani Y., Ikenoue N., Shinohara K., Watanabe K., and Fukaya T. Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. Circulation 108 (2003) 808-813
27. Ruiz-Sanz J.I., Navarro R., Martinez R., et al. 17beta-estradiol affects in vivo the low density lipoprotein composition, particle size, and oxidizability. Free Radic Biol Med 31 (2001) 391-397
28. Vieira O.V., Laranjinha J.A., Madeira V.M., and Almeida L.M. Rapid isolation of low density lipoproteins in a concentrated fraction free from water-soluble plasma antioxidants. J Lipid Res 37 (1996) 2715-2721
29. Peterson G.L. A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 83 (1977) 346-356
30. Esterbauer H., Gebicki J., Puhl H., and Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL. Free Radic Biol Med 13 (1992) 341-390
31. O'Neal D., Harrip P., Dragicevic G., Rae D., and Best J.D. A comparison of LDL size determination using gradient gel electrophoresis and light-scattering methods. J Lipid Res 39 (1998) 2086-2090
32. Lepage G., and Roy C.C. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 27 (1986) 114-120
33. Kanji S.S., Kuohung W., Labaree D.C., and Hochberg R.B. Regiospecific esterification of estrogens by lecithin:cholesterol acyltransferase. J Clin Endocrinol Metab 84 (1999) 2481-2488
34. Meng Q.H., Hockerstedt A., Heinonen S., Wahala K., Adlercreutz H., and Tikkanen M.J. Antioxidant protection of lipoproteins containing estrogens: in vitro evidence for low- and high-density lipoproteins as estrogen carriers. Biochim Biophys Acta 1439 (1999) 331-340
35. Lanza E., Forman M.R., Johnson E.J., Muesing R.A., Graubard B.I., and Beecher G.R. alpha-Tocopherol concentrations in plasma but not in lipoproteins fluctuate during the menstrual cycle in healthy premenopausal women. J Nutr 128 (1998) 1150-1155
36. Chait A., Brazg R.L., Tribble D.L., and Krauss R.M. Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B. Am J Med 94 (1993) 350-356
37. Lapointe A., Couillard C., and Lemieux S. Effects of dietary factors on oxidation of low-density lipoprotein particles. J Nutr Biochem 17 (2006) 645-658
38. Mesa M.D., Buckley R., Minihane A.M., and Yaqoob P. Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on the oxidizability and thrombogenicity of low-density lipoprotein. Atherosclerosis 175 (2004) 333-343